Epiminder Accelerates US Rollout with Strong DETECT Progress and Next-Gen Device on Track
Epiminder has leveraged its $125 million IPO to advance clinical enrolments, boost Medicare reimbursement, and develop its next-generation Minder device, positioning for a commercial launch in early 2028.
- 50 patients enrolled ahead of schedule in DETECT study
- 20 leading US clinical sites active including Mayo Clinic and Stanford
- Medicare proposes 14% reimbursement increase for 2027
- Next-generation Minder device design completion targeted mid-2027
- A$75.8 million cash supports operations well into 2028
DETECT Study Surges Ahead of Schedule
Epiminder Limited (ASX:EPI) has reported a significant operational leap in FY26, with the enrolment of 50 patients in its pivotal DETECT reimbursement study well ahead of the original mid-2026 guidance. This study, which now spans 20 prestigious US clinical sites including the Mayo Clinic, Harvard, Stanford, Yale, Duke, and the University of Pennsylvania, aims to enrol 210 patients by mid-2027. The multi-centre, randomised, controlled trial is designed to demonstrate the clinical and cost-effectiveness of the Minder System in managing drug-resistant epilepsy, a market estimated at up to US$1.1 billion annually.
Chief Medical Officer Professor Mark Cook’s recent tour of participating hospitals underscored robust clinical enthusiasm for the Minder device, with neurologists identifying potential applications beyond the initial target cohort. This momentum bolsters confidence in meeting recruitment targets critical to establishing reimbursement and payer adoption in the US.
Medicare Reimbursement Boosts Commercial Viability
Medicare has proposed a 14% increase in the reimbursement rate for the Minder procedure in 2027, from US$27,700 in 2026 to US$31,600, pending finalisation in November. This favourable adjustment supports Epiminder’s targeted average selling price of US$25,000 and reflects growing recognition of the Minder System’s clinical value in providing continuous, objective EEG monitoring over months or years.
The procedure also remains eligible for Transitional Pass-Through payment for outpatient settings, which Epiminder plans to pursue strategically to maximise revenue streams post-commercial launch. These reimbursement developments are pivotal as the company prepares for a broader US commercial rollout targeted for the first half of 2028.
Next-Generation Minder Device Progresses on Track
Robust Financial Position Supports Growth Path
The company’s financial footing has been significantly strengthened by its December 2025 IPO, which raised A$125 million. After accounting for IPO costs and a $15.8 million settlement of historical R&D tax claims, Epiminder closed FY26 with a healthy cash balance of A$75.8 million and zero debt. Operating cash outflows in the second half of FY26 were approximately A$14 million, below prior guidance, reflecting timing benefits that are expected to reverse in FY27.
Looking ahead, Epiminder anticipates a net cash outflow of A$45-48 million in FY27, driven by peak activity in the DETECT study and next-generation device development. Importantly, these costs are expected to decline materially from FY28 onward, aligning with the company’s transition toward commercial sales.
CEO Dr Rohan Hoare highlighted the transformational nature of FY26, underscoring the company’s clear operational pathway and sufficient funding to reach key milestones. The company plans to host an investor webinar on 30 July 2026 to update stakeholders on progress since the IPO.
Bottom Line?
Epiminder’s execution on clinical enrolment, reimbursement, and next-gen device development sets a solid foundation for its anticipated US commercial launch in early 2028, though successful completion of these milestones remains critical.
Questions in the middle?
- Will the DETECT study enrolment maintain its accelerated pace through to mid-2027?
- How will the final Medicare reimbursement ruling in November impact pricing and market access?
- What are the potential challenges in scaling manufacturing and securing FDA clearance for the next-generation Minder device?
